Breaking News

Hitachi Chemical Acquires Remaining Stake in PCT for $75M

Redefines Caladrius as a cell therapeutics-only development company with multiple technology platforms

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hitachi Chemical Co. America, Ltd. will acquire the remaining 80.1% ownership in PCT, LLC, a Caladrius Biosciences subsidiary, for $75 million in cash. Caladrius is also eligible to receive an additional cash payment of $5 million if PCT achieves certain revenue-based milestones. The closing, subject to approval and customary closing conditions, is expected to occur in May.   PCT is a cell therapy development and manufacturing services provider and is currently 19.9% owned by Hitachi Chemical....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters